Cell and small animal models for phenotypic drug discovery

M Szabo, S Svensson Akusjärvi, A Saxena… - Drug Design …, 2017 - Taylor & Francis
M Szabo, S Svensson Akusjärvi, A Saxena, J Liu, G Chandrasekar, SS Kitambi
Drug Design, Development and Therapy, 2017Taylor & Francis
The phenotype-based drug discovery (PDD) approach is re-emerging as an alternative
platform for drug discovery. This review provides an overview of the various model systems
and technical advances in imaging and image analyses that strengthen the PDD platform. In
PDD screens, compounds of therapeutic value are identified based on the phenotypic
perturbations produced irrespective of target (s) or mechanism of action. In this article,
examples of phenotypic changes that can be detected and quantified with relative ease in a …
The phenotype-based drug discovery (PDD) approach is re-emerging as an alternative platform for drug discovery. This review provides an overview of the various model systems and technical advances in imaging and image analyses that strengthen the PDD platform. In PDD screens, compounds of therapeutic value are identified based on the phenotypic perturbations produced irrespective of target(s) or mechanism of action. In this article, examples of phenotypic changes that can be detected and quantified with relative ease in a cell-based setup are discussed. In addition, a higher order of PDD screening setup using small animal models is also explored. As PDD screens integrate physiology and multiple signaling mechanisms during the screening process, the identified hits have higher biomedical applicability. Taken together, this review highlights the advantages gained by adopting a PDD approach in drug discovery. Such a PDD platform can complement target-based systems that are currently in practice to accelerate drug discovery.
Taylor & Francis Online